2024
|
P/S
|
Pharmaceutical preparations for the treatment of cancer, central nervous system diseases, and hem... |
2023
|
Invention
|
Chimeric poxviruses |
|
Invention
|
Fusion protein comprising a surfactant-protein-d and a member of the tnfsf |
|
Invention
|
Recombinant virus expressing interleukin-12 |
|
Invention
|
Personalized vaccine.
The present invention generally relates to a personalized cancer vaccine c... |
2022
|
Invention
|
Immunotherapeutic vaccine and antibody combination therapy.
The present invention relates to a c... |
|
Invention
|
Novel combinations of antibodies and uses thereof.
The present invention generally relates to a ... |
|
Invention
|
Novel combinations of antibodies and uses thereof. The present invention generally relates to a c... |
|
Invention
|
The polarity and specificity of sars-cov2 -specific t lymphocyte responses as a biomarker of dise... |
2021
|
Invention
|
Treatment of immune depression.
The present invention is in the field of immunotherapy. The inve... |
|
Invention
|
Treatment of immune depression. The present invention is in the field of immunotherapy. The inven... |
2020
|
Invention
|
Process for designing a recombinant poxvirus for a therapeutic vaccine.
The present invention ge... |
|
Invention
|
Process for designing a recombinant poxvirus for a therapeutic vaccine. The present invention gen... |
|
Invention
|
Combination of a poxvirus encoding hpv polypeptides with an anti-pd-l1 antibody.
The present inv... |
|
Invention
|
Combination of a poxvirus encoding hpv polypeptides and il-2 with an anti-pd-l1 antibody. The pre... |
|
Invention
|
Combination of oncolytic virus with immune checkpoint modulators.
The present invention provides... |
|
P/S
|
Downloadable bioinformatics software for tracking and analyzing cancer diagnoses; downloadable ar... |
2019
|
Invention
|
M2-defective poxvirus.
The present invention is in the field of oncolytic viruses. The invention... |
|
Invention
|
M2-defective poxvirus. The present invention is in the field of oncolytic viruses. The invention ... |
|
Invention
|
Immunosuppressive m2 protein. The invention is in the field of immunity and provides a poxviral p... |
|
Invention
|
Oncolytic virus for expression of immune checkpoint modulators. The present invention provides an... |
|
Invention
|
Production of viral vaccines on an avian cell line.
The present invention relates to the use of ... |
|
Invention
|
Production of viral vaccines on an avian cell line. The invention relates to the use of the immor... |
|
Invention
|
Anti-ctla-4 antibodies and their use in depleting ctla-4-positive cells. Described are novel anti... |
|
Invention
|
Novel antibodies and nucleotide sequences, and uses thereof. Described are novel anti-CTLA-4 anti... |
|
Invention
|
Parapoxvirus vectors.
The present invention is in the field of viral immunotherapy. The inventio... |
|
Invention
|
Parapoxvirus vectors. The present invention is in the field of viral immunotherapy. The invention... |
|
Invention
|
Methods for treating or preventing hbv infection or hbv related diseases. The present invention r... |
2018
|
Invention
|
Composition for treating hbv infection. The present invention provides a composition comprising h... |
|
Invention
|
Oncolytic viruses expressing agents targeting metabolic immune modulators. The present invention ... |
|
Invention
|
Personalized vaccine. The present invention generally relates to a personalized cancer vaccine co... |
|
Invention
|
Personalized vaccine comprising a recombinant poxvirus expressing a fusioin of nepopeptides. The ... |
2017
|
Invention
|
Oncolytic viruses and therapeutic molecules.
The present invention relates to an oncolytic virus... |
|
Invention
|
Oncolytic viruses and therapeutic molecules. The present invention relates to an oncolytic virus ... |
|
Invention
|
Cowpox-based oncolytic vectors. The present invention relates to a cowpox virus comprising at lea... |
|
P/S
|
Therapeutic vaccines in oncology; immunotherapy products in
oncology; preparation of therapeutic... |
|
P/S
|
Therapeutic vaccines in oncology; immunotherapy products, namely, pharmaceutical products for the... |
|
P/S
|
Therapeutic vaccines in oncology; customized immunotherapy
products; therapeutic vaccine prepara... |
|
P/S
|
Therapeutic vaccines in oncology; customized immunotherapy products, namely, pharmaceutical prepa... |
|
Invention
|
Immunotherapeutic product and mdsc modulator combination therapy.
The present invention provides... |
|
Invention
|
Immunotherapeutic product and mdsc modulator combination therapy. The present invention provides ... |
|
Invention
|
Combination therapy with cpg tlr9 ligand.
The present invention generally relates to an immunost... |
|
Invention
|
Combination therapy with cpg tlr9 ligand. The present invention generally relates to an immunosti... |
2016
|
Invention
|
Hbv polymerase mutants. The present invention relates to polymerase HBV mutant polypeptides compr... |
|
Invention
|
Composition for treating hbv infection.
The present invention provides a composition comprising ... |
|
P/S
|
Pharmaceutical products for cancer treatment; pharmaceutical
products for lung cancer treatment;... |
|
Invention
|
Combination product with autophagy modulator. The present invention relates to a combination prod... |
|
Invention
|
Immunotherapeutic vaccine and antibody combination therapy. The present invention relates to a co... |
2015
|
Invention
|
Stable liquid vaccinia virus formulations. The present invention relates to liquid formulations o... |
|
Invention
|
Combination of oncolytic virus with immune checkpoint modulators. The present invention provides ... |
|
Invention
|
Fusion of heterooligomeric mycobacterial antigens. Mycobacterium infection. |
2013
|
P/S
|
Research and scientific studies in the fields of chemistry, [ bacteriology, ] genetics, human [ a... |